[Pubmed] COVID-19 and myasthenia gravis: A review of neurological implications of the SARS-COV-2

[RSS-Bot]

Brain Behav. 2022 Oct 28:e2789. doi: 10.1002/brb3.2789. Online ahead of print.

ABSTRACT

INTRODUCTION: This review highlights the potential mechanisms of neuromuscular manifestation of COVID-19, especially myasthenia gravis (MG).

METHODS: An extensive literature search was conducted by two independent investigators using PubMed/MEDLINE and Google Scholar from its inception to December 2020.

RESULTS: Exacerbations of clinical symptoms in patients of MG who were treated with some commonly used COVID-19 drugs has been reported, with updated recommendations of management of symptoms of neuromuscular disorders. Severe acute respiratory syndrome coronavirus 2 can induce the immune response to trigger autoimmune neurological disorders.

CONCLUSIONS: Further clinical studies are warranted to indicate and rather confirm if MG in the setting of COVID-19 can pre-existent subclinically or develop as a new-onset disease.

PMID:36306401 | DOI:10.1002/brb3.2789


Source: https://pubmed.ncbi.nlm.nih.gov/3630640 ... 6&v=2.17.8